key: cord-0891399-m495uxt4
authors: Uckun, Fatih M.; Tuzcu, Mehmet; Gitterle, Marcus; Volk, Michael; Sahin, Kazim
title: Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders
date: 2021-01-05
journal: bioRxiv
DOI: 10.1101/2021.01.03.424883
sha: 7795f52086f0a4c878a571f5fc965b8dee41cfc8
doc_id: 891399
cord_uid: m495uxt4

Here, we demonstrate that our anti-sepsis and COVID-19 drug candidate Rejuveinix (RJX) substantially improves the survival outcome in the LPS-GalN animal model of sepsis and multi-organ failure. One hundred (100) percent (%) of untreated control mice remained alive throughout the experiment. By comparison, 100% of LPS-GalN injected mice died at a median of 4.6 hours. In contrast to the invariably fatal treatment outcome of vehicle-treated control mice, 40% of mice treated with RJX (n=25) remained alive with a 2.4-fold longer median time survival time of 10.9 hours (Log-rank X2=20.60, P<0.0001). Notably, RJX increased the tissue levels of antioxidant enzymes SOD, CAT, and GSH-Px, and reduced oxidative stress in the brain. These findings demonstrate the clinical impact potential of RJX as a neuroprotective COVID-19 and sepsis drug candidate.

Severe viral sepsis caused by SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), shows a rapid progression associated with a cytokine release syndrome (CRS) and a high case fatality rate due to the development of ARDS and multi-organ failure in high-risk COVID-19 patients (1, 2) . Our anti-sepsis drug candidate, Rejuveinix (RJX), is a rationally-designed formulation of naturally occurring anti-oxidants and anti-inflammatory compounds with a significant clinical impact potential for COVID-19 associated viral sepsis (3, 4) . RJX showed a very favorable clinical safety profile in a recently completed double-blind, placebo-controlled, randomized, two-part, ascending dose-escalation Phase 1 study in healthy volunteers (Protocol No. RPI003; ClinicalTrials.gov Identifier: NCT03680105) [18] . It has now entered a randomized double-blind, placebo-controlled Phase 2 study in hospitalized patients with critical COVID-19.

More than a third of patients with COVID-19, especially those with severe to critical COVID-19 who managed on an intensive care unit (ICU) develop central nervous system (CNS) symptoms and signs (e.g., headache, dizziness, ataxia, seizure, delirium, confusion, impaired consciousness) consistent with CNS involvement and /or neurological complications (6) (7) (8) (9) (10) (11) (12) (13) .

Cerebrovascular complications of viral sepsis, including ischemic or hemorrhagic stroke, CNS involvement in CRS, hypoxia as well as the interplay of comorbidities have been implicated as contributing factors (6) (7) (8) (9) (10) (11) (12) (13) . Due to the neuro-invasive capability of SARS-CoV-2, acute disseminated encephalomyelitis (ADEM) and viral encephalitis have also been suspected in some patients (13) .

Oxidative stress caused by the massive production of reactive oxygen species (ROS) is thought to play a major role in the pathogenesis of severe viral sepsis in COVID-19 (14) .

Chaudry et al. recently proposed that reactive oxygen intermediates and oxidative stress may play an important role in the pathophysiology of COVID-19 associated CNS disease, reminiscent of their role in Parkinson's disease (15) . Notably, RJX exhibited potent anti-oxidant activity and mitigated lipid peroxidation in both prophylactic and therapeutic settings, as reflected by significantly decreased tissue MDA levels and normalization of the tissue levels of the antioxidant enzymes SOD, CAT, and GSH-Px as well as ascorbic acid (5) . The primary objective of the present study was to obtain experimental proof of concept that RJX can mitigate sepsis-associated oxidative stress in the brain.

RJX is a proprietary composition of naturally occurring anti-oxidants and antiinflammatory agents which, in combination, provide potent and immediate tissue protection. Its ingredients include ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine hydrochloride, riboflavin 5' phosphate, niacinamide, pyridoxine hydrochloride, and calcium Dpantothenate. RJX is a two-vial system and A and B are each of the two vials. Vial A contains the active ingredients and minerals whereas Vial B contains the buffer, sodium bicarbonate as the Vial A content is acidic (5).

The ability of RJX, DEX and RJX plus DEX to prevent fatal shock, ARDS, and multi- Lipid peroxidation as a biomarker of oxidative stress was determined and expressed as the amount of malondialdehyde (MDA, nmol/g tissue) in the brain, as previously described (5).

The enzymatic activities of SOD, CAT and GSH-Px in the brain specimens were determined using the commercially available kits (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's procedures (5) .

Statistical analyses employed standard methods, including analysis of variance (ANOVA) and/or, nonparametric analysis of variance (Kruskall-Wallis) using the SPSS statistical program (IBM, SPPS Version 21), as reported (5) . Furthermore, the Kaplan-Meier method, log-rank chi-square test, was used to investigate survival and fatality in each group. Pvalues <0.05 were considered significant.

One hundred (100) percent (%) of untreated control mice remained alive throughout the experiment. By comparison, 100% of LPS-GalN injected mice died at a median of 4.6 hours (Figure 1) . RJX was examined for its protective activity at a dose level, which is >10-fold lower than its maximum tolerated dose (MTD) of 0.759 mL/kg for human subjects (viz.; 4.2 mL/kg of a 6-fold diluted solution). RJX-treated mice had an improved survival outcome after being injected with LPS-GalN. In contrast to the invariably fatal treatment outcome of vehicle-treated control mice, 40% of mice treated with RJX (n=25) remained alive with a 2.4-fold longer median time survival time of 10.9 hours (Log-rank X 2 =20.60, P<0.0001) (Figure 1) .

No histopathologic brain lesions were observed in any of the mice challenged with LPS-GalN. However, the brain MDA levels measuring lipid peroxidation were markedly elevated, and the levels of the antioxidant enzymes SOD, CAT, and GSH-Px in the brain were markedly reduced in LPS-GalN treated mice consistent with severe oxidative stress (Figure 2) . RJX decreased the brain MDA levels and normalized in a dose-dependent manner the reduced levels of the antioxidant enzymes SOD, CAT, and GSH-Px.

Patients with high-risk COVID-19 are in urgent need of treatment platforms capable of preventing the disease progression and/or reducing the case mortality rate by stopping or reversing the pulmonary as well as systemic inflammatory process that cause the ARDS and culminate in multi-organ failure (1, 2, 16) . Here we extend our previous study and provide experimental evidence that RJX is capable of improving the survival outcome in the LPS-GalN mouse model of fatal sepsis. SOD, CAT, and GSH-Px are three pivotal antioxidant defense enzymes, and their levels are altered by the level of oxidative stress that is a hallmark of severe inflammation of sepsis (14) . Oxidative stress caused by massive production of reactive oxygen species (ROS) is thought to play a major role in the pathogenesis of severe viral sepsis in COVID-19 as well (14) .

The MDA levels were markedly elevated in the brain specimens of the LPS-GalN challenged mice which is consistent with increased lipid peroxidation. In parallel, the levels of the antioxidant enzymes SOD, CAT, and GSH-Px were profoundly suppressed due to severe oxidative stress. RJX exhibited potent anti-oxidant activity and mitigated lipid peroxidation, as reflected by significantly decreased tissue MDA levels and normalization of the tissue levels of the antioxidant enzymes SOD, CAT, and GSH-Px as well as ascorbic acid. We hypothesize that RJX will shorten the time to resolution of ARDS and viral sepsis in COVID-19 patients by preventing the development of a fulminant cytokine storm as well as reversing the cytokinemediated multi-system inflammatory process and oxidative stress, thereby mitigating the inflammatory organ injury. 

Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation

Review of the Clinical Characteristics of Coronavirus Disease

Rationale For A Randomized, Placebo-Controlled, Phase 2 Study Of Rejuveinix (RJX) in COVID-19 Patients With Acute Lung Injury And Hypoxemic Respiratory Failure

Clinical Impact Potential Of Rejuveinix (RJX) For Prevention Of Fatal Acute Respiratory Distress Syndrome (ARDS) And Multi-Organ Failure

Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi-Organ Failure

COVID-19 Neurological Manifestations

A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View

Nervous system involvement after infection with COVID-19 and other coronaviruses

COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance. Cells

Brain and COVID-19 Crosstalk: Pathophysiological and Psychological Manifestations

Fragile Endothelium and Brain Dysregulated Neurochemical Activity in COVID-19

The neurological manifestations of COVID-19: a review article

Considerations around the SARS-CoV-2 Spike Protein with Particular Attention to COVID-19 Brain Infection and Neurological Symptoms

Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression

COVID-19 and Parkinson's Disease: Shared Inflammatory Pathways Under Oxidative Stress

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

catalase (CAT; Panel C) and Glutathione peroxidase (GSHPx; Panel D) in the lipopolysaccharide-galactosamine (LPS-GalN) challenged mice. Each bar represents the mean and standard deviation for the measured parameter of mice from each specific treatment group (6 mice/group). BALB/C mice were treated with i.p injections of 6-fold diluted RJX (4.2 mL/kg, 0.5 ml/mouse) or vehicle (NS) 2 hours before or post-injection of LPS-GalN. Except for untreated mice (Control), each mouse received 0.5 ml of LPS-GalN (consisting of 100 ng of LPS plus 8 mg of D-galactosamine) i.p. (ANOVA and Tukey's post-hoc test

The sponsor did not participate in the collection of data. Two of the authors (F.M.U, and M.V) who participated in the analysis and decision to submit the manuscript for publication are affiliated with the sponsor.